{"organizations": [], "uuid": "775ac7d14589b72ce34780de097fbe78d5ae40f4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/roche-immunotherapy/roches-tecentriq-combination-to-get-speedy-fda-review-idUSFWN1SB1G5", "country": "US", "domain_rank": 408, "title": "Roche's Tecentriq combination to get speedy FDA review", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-07T13:23:00.000+03:00", "replies_count": 0, "uuid": "775ac7d14589b72ce34780de097fbe78d5ae40f4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/roche-immunotherapy/roches-tecentriq-combination-to-get-speedy-fda-review-idUSFWN1SB1G5", "ord_in_thread": 0, "title": "Roche's Tecentriq combination to get speedy FDA review", "locations": [], "entities": {"persons": [{"name": "roche", "sentiment": "negative"}, {"name": "michael shields", "sentiment": "none"}, {"name": "john miller", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, May 7 (Reuters) - Rocheâ€™s immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get a speeded-up review by U.S. regulators for use in initial treatment of people with a common form of lung cancer, the Swiss drugmaker said on Monday.\nRoche has already announced results of clinical trials that showed the combination boosted survival benefit compared to older treatments. (Reporting by John Miller; Editing by Michael Shields)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-07T13:23:00.000+03:00", "crawled": "2018-05-07T10:01:55.016+03:00", "highlightTitle": ""}